Sofinnova Venture Partners
SelectiveFiled to raiseMenlo Park, CABiotech & pharma, Medical devices, Healthcare servicesLast fund filed December 2024
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Sofinnova Venture Partners XII | December 2024 | $550M | $527M | 78 |
| Sofinnova BioEquities Enhanced Master Fund | October 2022 | Indefinite | $87M | 26 |
| Sofinnova Venture Partners XI | September 2021 | $500M | $500M | 50 |
| Sofinnova BioEquities | 2017 | Indefinite | $377M | 77 |
| Sofinnova Venture Partners X | August 2016 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Garheng KongNot on the current fund | Slowing | Medical devices, Biotech & pharma, Healthcare services | 17 |
Categories of Sofinnova Venture Partners’s own portfolio companies, based on 56 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Healthquest Partners | 17 | Ajax Health II, Ajax Health III, Alcresta Therapeutics, ALIMERA SCIENCES, AVEDRO, Bardy Diagnostics, CASTLE BIOSCIENCES, CleanSlate Centers, First Aid Beverages, Home Hospital Newco, Magnolia Medical Technologies, MELINTA THERAPEUTICS, INC. /NEW/, Nomad Health, Strongbridge Biopharma plc, Trice Medical, Venus Concept, Venus Concept |
| Venbio Global Strategic | 5 | Aeovian Pharmaceuticals, Apellis Pharmaceuticals, Checkmate Pharmaceuticals, Marea Therapeutics, RayzeBio |
| Vivo Capital | 5 |
| $650M |
| $596M |
| 57 |
| HealthQuest Partners II | 2016 | $225M | $225M | 53 |
| Sofinnova Venture Partners IXFiled to raise in 2014, with no closing reported yet. | 2014 | $500M | $0 | 0 |
| Sofinnova HealthQuest Partners | July 2013 | $110M | $65M | 26 |
| 1 |
| Maha Katabi | Slowing | Biotech & pharma | 9 | 1 |
| Anand MehraNot on the current fund | Quiet | Biotech & pharma | 6 | 0 |
| James Healy | Quiet | Biotech & pharma, Digital health | 12 | 0 |
| Michael PowellNot on the current fund | Quiet | Biotech & pharma, Aerospace & defense, Healthcare services | 15 | 0 |
| Sarah BhagatNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Sofinnova Venture Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Aclaris Therapeutics, Ascendis Pharma A/S, AVEDRO, Bolt Biotherapeutics, Merus N.V. |
| Longitude Capital | 3 | BioAge Labs, Venus Concept, Vera Therapeutics |
| NEA | 3 | Amplyx Pharmaceuticals, Inozyme Pharma, SYNLOGIC |
| Abingworth Bioventures | 2 | AVEDRO, EFFECTOR THERAPEUTICS |
| Aisling Capital | 2 | Aclaris Therapeutics, Ajax Health II |
| Frazier Life Sciences | 2 | Alcresta Therapeutics, Iterum Therapeutics Bermuda |
| Kleiner Perkins | 2 | Star Therapeutics, Vera Therapeutics |
| Nexeption Capital | 2 | Aclaris Therapeutics, CATALYST BIOSCIENCES |
| Polaris Partners | 2 | Ajax Health III, Nomad Health |
| Westlake Biopartners | 2 | Star Therapeutics, Vera Therapeutics |
| Advent Life Sciences | 1 | Iterum Therapeutics Bermuda |
| AlleyCorp | 1 | Nomad Health |
| ARCH Venture Partners | 1 | Seaport Therapeutics |
A shared board seat: a company where filings name a Sofinnova Venture Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.